Rethinking the diagnostic criteria of polycythemia vera

Leukemia

Volumn 28, Issue 6, 2014, Pages 1191-1195

  Barbui, T ^a   Thiele, J ^b   Vannucchi, A M ^c   Tefferi, A ^d  

^a PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF FLORENCE   (Italy)

^d MAYO CLINIC   (United States)

Author keywords

bone marrow histology; diagnostic criteria; masked polycythemia; polycythemia vera; risk factors for survival

Indexed keywords

HEMOGLOBIN; MOLECULAR MARKER; ERYTHROPOIETIN;

BIOPSY; BONE MARROW; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; GENE MUTATION; HEMATOCRIT; HUMAN; MEDICAL SOCIETY; PATIENT MONITORING; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; SURVIVAL; WORLD HEALTH ORGANIZATION; ACUTE LEUKEMIA; ARTERY THROMBOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ERYTHROCYTE VOLUME; ERYTHROCYTOSIS; LEUKOCYTOSIS; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MYELOFIBROSIS; PHLEBOTOMY; THROMBOCYTHEMIA; THROMBOCYTOSIS; VALIDITY;

HEMATOCRIT; HUMANS; POLYCYTHEMIA VERA; WORLD HEALTH ORGANIZATION;

EID: 84902077783     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.380     Document Type: Review

References (62)

1. Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD. Treatment of polycythemia vera: A summary of clinical trials conducted by the Polycythemia Vera Study Group. In: Wasserman LR, Berk PD, Berlin NI (eds). Polycythemia Vera and the Myeloproliferative Disorders. W.B. Saunders: Philadelphia, 1995, pp 166-194.
2. McMullin MF, Reilly JT, Campbell P, Bareford D, Green AR, Harrison CN et al. Amendment to the guideline for diagnosis and investigation of polycythaemia/ erythrocytosis. Br J Haematol 2007; 138: 821-822. (Pubitemid 47313223)
3. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092-1097. (Pubitemid 47281402)
4. Thiele J, Kvasnicka HM, Orazi A, Tefferi A, Birgegard G. Polycythaemia vera. In: Swerdlow S, Campo E, Harris N et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2008, pp 40-43.
5. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006; 355: 2452-2466. (Pubitemid 44903749)
6. James C, Ugo V, Le Coue dic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
7. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790. (Pubitemid 40570926)
8. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397. (Pubitemid 40544655)
9. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061. (Pubitemid 40386783)
10. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F negative polycythemia vera. Leukemia 2007; 21: 1960-1963. (Pubitemid 47299970)
11. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459-468. (Pubitemid 46193073)
12. Spivak JL. Polycythemia vera: Myths, mechanisms, and management. Blood 2002; 100: 4272-4290. (Pubitemid 35429665)
13. Johansson PL, Safai-Kutti S, Kutti J. An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: A study of patients with polycythaemia vera and apparent polycythaemia. Br J Haematol 2005; 129: 701-705. (Pubitemid 40825832)
14. Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: An alternative proposal. Blood 2008; 112: 231-239.
15. Tefferi A. The rise and the fall of red cell mass measurement in polycythemia vera. Curr Hematol Malign Rep 2005; 4: 213-217.
16. Alvarez-Larran A, Ancochea A, Angona A, Pedro C, Garcia-Pallarols F, Martinez-Aviles L et al. Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia. Haematologica 2012; 97: 1704-1707.
17. Silver RT, Chow W, Orazi A, Arles SP, Goldsmith SJ. Evaluation of WHO criteria for diagnosis of polycythemia vera: A prospective analysis. Blood 2013; 122: 1881-1886.
18. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. The value of bone marrow histology indifferentiating between early stage polycythemia vera and secondary (reactive) polycythemias. Haematologica 2001; 86: 368-374. (Pubitemid 32428495)
19. Thiele J, Kvasnicka HM, Diehl V. Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. Acta Haematol 2005; 113: 213-219. (Pubitemid 40911544)
20. Gianelli U, Iurlo A, Vener C, Moro A, Fermo E, Bianchi P et al. The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the "early" prepolycythemic phase of polycythemia vera and essential thrombocythemia. Am J Clin Pathol 2008; 30: 336-342.
21. Barbui T, Thiele J, Gisslinger H, Finazzi G, Carobbio A, Rumi E et al. Masked polycythemia vera (mPV): Results of an international study. Am J Hematol 2013; e-pub ahead of print 31 August 2013; doi:10.1002/ajh.23585.
22. Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007; 31: 737-740.
23. Ellis JT, Peterson P, Geller SA, Rappaport H. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin Hematol 1986; 23: 144-155.
24. Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol 1975; 12: 339-351.
25. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on PVSG protocols. Semin Hematol 1986; 23: 132-143.
26. Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 1999; 36: 9-13. (Pubitemid 29045497)
27. Pearson TC. Diagnosis and classification of erythrocytoses and thrombocytoses. Baillieres Clin Haematol 1998; 11: 695-720. (Pubitemid 29452759)
28. Pearson TC. Evaluation of diagnostic criteria in polycythemia vera. Semin Hematol 2001; 38: 21-24. (Pubitemid 32220623)
29. Messinezy M, Pearson TC. The classification and diagnostic criteria of the erythrocytoses (polycythaemias). Clin Lab Haem 1999; 21: 309-316. (Pubitemid 30007092)
30. McMullin MF, Bareford D, Campbell P, Green AR, Harrison C, Hunt B et al. Guidelines for the diagnosis, investigation and management of polycythaemia/ erythrocytosis. Br J Haematol 2005; 130: 174-195. (Pubitemid 41602518)
31. Pearson TC. Apparent polycythaemia. Blood Rev 1991; 5: 205-213.
32. Tefferi A. The rise and the fall of red cell mass measurement in polycythemia vera. Curr Hematol Rep 2005; 4: 213-217.
33. Sirhan S, Fairbanks VF, Tefferi A. Red cell mass and plasma volume measurements in polycythemia: Evaluation of performance and practical utility. Cancer 2005; 104: 213-215. (Pubitemid 40847771)
34. Ellis JT, Silver RT, Coleman M, Geller SA. The bone marrow in polycythemia vera. Semin Hematol 1975; 12: 433-444.
35. Ellis JT, Peterson P. The bone marrow in polycythemia vera. Pathol Ann 1979; 1: 383-403.
36. Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study. Leukemia 2013; 27: 1874-1881.
37. Thiele J, Kvasnicka HM. Diagnostic impact of bone marrow histopathology in polycythemia vera (PV). Histol Histopathol 2005; 20: 47.
38. Thiele J, Schneider G, Hoeppner B, Wienhold S, Zankovich R, Fischer R. Histomorphometry of bone marrow biopsies in chronic myeloproliferative disorders with associated thrombocytosis-features of significance for the diagnosis of primary (essential) thrombocythaemia. Virchows Arch 1988; (A) 413: 407-417.
39. Buhr T, Georgii A, Schuppan O, Amor A, Kaloutsi V. Histologic findings in bone marrow biopsies of patients with thrombocythemic cell counts. Ann Hematol 1992; 64: 286-291.
40. Georgii A, Buhr T, Buesche G, Kreft A, Choritz H. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leuk Lymphoma 1996; 22(Suppl 1): 15-29. (Pubitemid 26388528)
41. Georgii A, Buesche G, Kreft A. The histopathology of chronic myeloproliferative diseases. Baillieres Clin Haematol 1998; 11: 721-749. (Pubitemid 29452760)
42. Thiele J, Kvasnicka HM, Muehlhausen K, Walter S, Zankovich R, Diehl V. Polycythemia rubra vera versus secondary polycythemias. A clinicopathological evaluation of distinctive features in 199 patients. Pathol Res Pract 2001; 197: 77-84. (Pubitemid 32194499)
43. Thiele J, Kvasnicka HM, Diehl V. Standardization of bone marrow features-does it work in hematopathology for histological discrimination of different disease patterns? Histol Histopathol 2005; 20: 633-644. (Pubitemid 40468281)
44. Thiele J, Kvasnicka HM. The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Curr Hematol Malig Rep 2009; 4: 33-401.
45. Buhr T, Georgii A, Choritz H. Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification. Pathol Res Pract 1993; 189: 121-132. (Pubitemid 23123616)
46. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Randi ML et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood 2012; 119: 2239-2241.
47. Thiele J, Kvasnicka HM, Facchetti F, Franco V, Van Der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005; 90: 1128-1132. (Pubitemid 41323513)
48. McMullin MF. The classification and diagnosis of erythrocytosis. Int J Lab Hem 2008; 30: 447-459.
49. Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: The 2008 WHO classification. Am J Hematol 2010; 85: 62-66.
50. Pierre R, Imbert M, Thiele J, Vardiman J, Brunning R, Flandrin G. Polycythemia vera. In: Jaffe ES, Harris HL, Stein H, Vardiman JW (eds). Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2001, pp 32-34.
51. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22.
52. Tefferi A. Diagnosing polycythemia vera: A paradigma shift. Mayo Clin Proc 1999; 74: 159-162. (Pubitemid 29085213)
53. Mossuz P, Girodon F, Donnard M, Latger-Cannard V, Dobo I, Boiret N et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 2004; 89: 1194-1198.
54. Lemoine F, Najman A, Baillou C, Stachowiak J, Boffa G, Aegerter P et al. A prospective study of the value of bone marrow erythroid progenitor cultures in polycythemia. Blood 1986; 68: 996-1002. (Pubitemid 17186372)
55. Weinberg RS, Worsley A, Gilbert HS, Cuttner J, Berk PD, Alter BP. Comparison of erythroid progenitor cell growth in vitro in polycythemia vera and chronic myelogenous leukemia: Only polycythemia vera has endogenous colonies. Leuk Res 1989; 13: 331-338. (Pubitemid 19105686)
56. Juvonen E, Ikkala E, Oksanen K, Ruutu T. Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: Diagnostic value and correlation to complications. Br J Haematol 1993; 83: 192-197. (Pubitemid 23060913)
57. Gruppo Italiano Studio Policitemia. Polycythemia vera: The natural history of 1213 patients followed for 20 years. Ann Intern Med 1995; 123: 656-664.
58. Barbui T, Thiele J, Carobbio A, Gisslinger H, Finazzi G, Rumi E et al. Masked Polycythemia vera diagnosed according to WHO and BCSH classification. Am J Hematol 2013; e-pub ahead of print 26 October 2013; doi:10.1002/ajh.23617.
59. Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013; 368: 22-33.
60. Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian JJ, Lengfelder E et al. Revised response criteria for polycythemia vera and essential thrombocythemia: An ELN and IWG-MRT consensus project. Blood 2013; 121: 4778-4781.
61. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M et al. Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29: 761-770.
62. Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87: 285-293.